Nifuroxazide | CAS#965-52-6 | antibiotic

MedKoo Cat#: 561571 | Name: Nifuroxazide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nifuroxazide is an antibiotic used for the treatment of colitis and diarrhea in humans and non-humans.

Chemical Structure

Nifuroxazide

CAS#965-52-6

Theoretical Analysis

MedKoo Cat#: 561571

Name: Nifuroxazide

CAS#: 965-52-6

Chemical Formula: C12H9N3O5

Exact Mass: 275.0542

Molecular Weight: 275.22

Elemental Analysis: C, 52.37; H, 3.30; N, 15.27; O, 29.07

Price and Availability

Size	Price	Availability	Quantity
250mg	USD 210.00
500mg	USD 360.00
1g	USD 850.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Nifuroxazide; Ambatrol; Antinal; Bacifurane; Diafuryl; Diarlidan;

IUPAC/Chemical Name

4-Hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]benzamide

InChi Key

YCWSUKQGVSGXJO-NTUHNPAUSA-N

InChi Code

InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+

SMILES Code

O=C(N/N=C/C1=CC=C([N+]([O-])=O)O1)C2=CC=C(O)C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Nifuroxazide is an effective inhibitor of STAT3.

In vitro activity:

Nifuroxazide inhibits the constitutive phosphorylation of STAT3 in MM (multiple myeloma) cells by reducing Jak kinase autophosphorylation, and leads to down-regulation of the STAT3 target gene Mcl-1. Nifuroxazide causes a decrease in viability of primary myeloma cells and myeloma cell lines containing STAT3 activation, but not normal peripheral blood mononuclear cells. Although bone marrow stromal cells provide survival signals to myeloma cells, nifuroxazide can overcome this survival advantage. Reference: Blood. 2008 Dec 15;112(13):5095-102. https://pubmed.ncbi.nlm.nih.gov/18824601/

In vivo activity:

Nifuroxazide significantly inhibited tumor growth without obvious side effects in the A375-bearing mice model by inducing apoptosis and reducing cell proliferation and metastasis. Notably, nifuroxazide significantly inhibited pulmonary metastases, which might be associated with the decrease of myeloid-derived suppressor cells (MDSCs). Reference: Sci Rep. 2016 Feb 2;6:20253. https://pubmed.ncbi.nlm.nih.gov/26830149/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	109.00
	DMSO	80.0	290.68
	DMSO:PBS (pH 7.2) (1:1)	0.5	1.82

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 275.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wang X, Ye J, Gao M, Zhang D, Jiang H, Zhang H, Zhao S, Liu X. Nifuroxazide inhibits the growth of glioblastoma and promotes the infiltration of CD8 T cells to enhance antitumour immunity. Int Immunopharmacol. 2023 Mar 14;118:109987. doi: 10.1016/j.intimp.2023.109987. Epub ahead of print. PMID: 36924564. 2. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC, Frank DA. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15;112(13):5095-102. doi: 10.1182/blood-2007-12-129718. Epub 2008 Sep 29. PMID: 18824601; PMCID: PMC2597607. 3. Amin FM, Sharawy MH, Amin MN, El-Sherbiny M, Said E, Salem HA, Ibrahim TM. Nifuroxazide mitigates doxorubicin-induced cardiovascular injury: Insight into oxidative/NLRP3/GSDMD-mediated pyroptotic signaling modulation. Life Sci. 2023 Feb 1;314:121311. doi: 10.1016/j.lfs.2022.121311. Epub 2022 Dec 19. PMID: 36549350. 4. Zhu Y, Ye T, Yu X, Lei Q, Yang F, Xia Y, Song X, Liu L, Deng H, Gao T, Peng C, Zuo W, Xiong Y, Zhang L, Wang N, Zhao L, Xie Y, Yu L, Wei Y. Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep. 2016 Feb 2;6:20253. doi: 10.1038/srep20253. Erratum in: Sci Rep. 2022 Jun 28;12(1):10920. PMID: 26830149; PMCID: PMC4735744.

In vitro protocol:

In vivo protocol:

1. Amin FM, Sharawy MH, Amin MN, El-Sherbiny M, Said E, Salem HA, Ibrahim TM. Nifuroxazide mitigates doxorubicin-induced cardiovascular injury: Insight into oxidative/NLRP3/GSDMD-mediated pyroptotic signaling modulation. Life Sci. 2023 Feb 1;314:121311. doi: 10.1016/j.lfs.2022.121311. Epub 2022 Dec 19. PMID: 36549350. 2. Zhu Y, Ye T, Yu X, Lei Q, Yang F, Xia Y, Song X, Liu L, Deng H, Gao T, Peng C, Zuo W, Xiong Y, Zhang L, Wang N, Zhao L, Xie Y, Yu L, Wei Y. Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep. 2016 Feb 2;6:20253. doi: 10.1038/srep20253. Erratum in: Sci Rep. 2022 Jun 28;12(1):10920. PMID: 26830149; PMCID: PMC4735744.

1: Hofnung M, Quillardet P, Michel V, Touati E. Genotoxicity of 2-nitro-7-methoxy-naphtho[2,1-b]furan (R7000): a case study with some considerations on nitrofurantoin and nifuroxazide. Res Microbiol. 2002 Sep;153(7):427-34. Review. PubMed PMID: 12405349. 2: Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy. 1995;41 Suppl 1:48-81. Review. PubMed PMID: 7671647.